Fosun Pharma Launches Phase I Clinical Trial of SRT-007 with RMB 321.9 Million Investment Targeting a USD 1.392 Billion Market

December 30,Fosun Pharmaceutical(600196/02196) announced that its holding subsidiary, Chengdu Xingrui Jingxuan Biotechnology Co., Ltd., has recently initiated the Phase I clinical trial of the integrated theranostic radiopharmaceutical project SRT-007 in China. The indication is for the diagnosis and treatment of PSMA-positive metastatic castration-resistant prostate cancer.

The project includes two injectable drugs: Gallium [68Ga] PSMA-0057 (diagnostic) and Lutetium [177Lu] PSMA-0057 (therapeutic). As of November 2025, the group's cumulative R&D investment in SRT-007 amounts to approximately 32.19 million yuan (unaudited; including licensing fees).

The radioactive drug targeting the same point that has been approved for marketing worldwide is Pluvicto by NOVARTIS AG, with global sales of $1.392 billion in 2024.

In the first three quarters of 2025, Fosun Pharmaceutical achieved revenue of 29.393 billion yuan and a net profit attributable to shareholders of 2.523 billion yuan.